Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed Johnson & Johnson reported promising year-long results for ICOTYDE™, a once-daily oral treatment for plaque psoriasis, confirming its effectiveness and safety.

Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed #United_States #Johnson_&_Johnson #Spring_House #Plaque_Psoriasis #ICOTYDE

A aprovação de um novo medicamento oral para psoríase em placas moderada a grave marca um avanço importante no tratamento da doença. Desenvolvido pela Johnson & Johnson, o Icotyde atua.

Matéria completa - regisandrade.com.br/pilula-contr...

#psoríase #icotyde #johnsonejohnson #medicamentooral

ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis Johnson & Johnson's ICOTYDE™ has received FDA approval as a novel oral treatment for moderate-to-severe plaque psoriasis, a significant advancement for patient care.

ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis #United_States #Johnson_&_Johnson #Spring_House #Plaque_Psoriasis #ICOTYDE